APA

Magenau J., Westervelt P., Khaled S., McGuirk J., Hari P., Eapen M., Becker P. S., Parkin B., Braun T., Logan B., Wang H., Jagasia M., Rowley S. D., Kim D. D. H., Schechter T., Frey N., Scott B., Churay T., Lieland S., Forman S. & Mineishi S. (20171214). A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. : Bone marrow transplantation.

Chicago

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker P S, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley S D, Kim D D H, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S and Mineishi S. 20171214. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. : Bone marrow transplantation.

Harvard

Magenau J., Westervelt P., Khaled S., McGuirk J., Hari P., Eapen M., Becker P. S., Parkin B., Braun T., Logan B., Wang H., Jagasia M., Rowley S. D., Kim D. D. H., Schechter T., Frey N., Scott B., Churay T., Lieland S., Forman S. and Mineishi S. (20171214). A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. : Bone marrow transplantation.

MLA

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker P S, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley S D, Kim D D H, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S and Mineishi S. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. : Bone marrow transplantation. 20171214.